Real-life data on first-line sunitinib and pazopanib therapy in metastatic renal cell carcinoma patients: A single center experience
No Thumbnail Available
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Zerbinis Publications
Access Rights
info:eu-repo/semantics/closedAccess
Abstract
Purpose: In this study, we aimed to compare the data of sunitinib and pazopanib used in the first-line treatment of metastatic renal cell carcinoma (RCC) cases and to evaluate the effective factors in terms of survival. Methods: The records of 125 patients with metastatic RCC admitted between January 2005 and February 2018 were retrospectively analyzed and 63 patients who received pazopanib or sunitinib were included in the study while 62 patients were excluded due to insufficient data. Clinical and histological characteristics, treatment responses, progression-free survival (PFS), and overall survival (OS) of the patients were compared. Results: Patients with metastatic RCC who received pazopanib or sunitinib as tyrosine kinase inhibitors (TKI) in first-line treatment were analyzed; 45 (71.4%) were male while 18 (28.6%) were female, and the median age was 60. 43 (68.3%) patients were treated with sunitinib and 20 (31.7%) with pazopanib. PFS of pazopanib and sunitinib were 10.6 and 7.2 months, respectively. Median OS was 14.5 months in patients receiving pazopanib and 13.6 months in those receiving sunitinib. There was no statistical difference in PFS and OS between both treatments. The median OS of clear-cell RCC was 15.2 months, while of non-clear-cell RCC was 7.7months. Conclusions: High ECOG score, non-clear-cell histology, presence of liver metastasis in metastatic RCC patients were found to be associated with shorter OS and PFS. Sunitinib and pazopanib produced similar OS and PFS rates in first-line treatment of metastatic RCC. © This work by JBUON is licensed under a Creative Commons Attribution 4.0 International License.
Description
Keywords
Overall Survival; Pazopanib; Renal Cell Carcinoma; Sunitinib, Pazopanib; Sunitinib; Angiogenesis Inhibitor; Antineoplastic Agent; Indazole Derivative; Pazopanib; Pyrimidine Derivative; Sulfonamide; Sunitinib; Adult; Aged; Article; Cancer Chemotherapy; Cancer Patient; Cancer Surgery; Cancer Survival; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Clinical Feature; Comparative Effectiveness; Controlled Study; Female; High Risk Population; Histopathology; Human; Human Tissue; Intermediate Risk Population; Kidney Metastasis; Major Clinical Study; Male; Overall Survival; Papillary Carcinoma; Patient History Of Nephrectomy; Progression Free Survival; Retrospective Study; Treatment Response; Comparative Study; Kidney Tumor; Middle Aged; Mortality; Pathology; Renal Cell Carcinoma; Survival Rate; Treatment Outcome; Very Elderly; Adult; Aged; Aged, 80 And Over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome
Journal or Series
Journal of B.U.ON.
WoS Q Value
Scopus Q Value
Q3
Volume
26
Issue
4
